Healthcare Industry News: Sutura
News Release - May 21, 2007
Sutura Announces Initial Product Launch of the 12F Superstitch Vascular Suturing Device
COMO, ITALY--(Healthcare Sales & Marketing Network)--May 21, 2007 -- Sutura, Inc. ("Sutura") (OTC BB:SUTU.OB ), an innovative developer of minimally invasive vascular suturing devices, announced today the initial product launch of the Company's 12F SuperStitch suturing device. Dr. Mario Galli performed multiple successful procedures today using the 12F SuperStitch at Santa Ana Hospital in Como Italy. Dr. Galli performed 14, 18 & 24F closures using a 12F SuperStitch placing multiple sutures in the femoral artery with, in each case, the device successfully closing the arteriotomy."The results of the initial launch of the 12F device, the only device that can close large bore holes in vessels, are yet another important milestone for Sutura," said Anthony Nobles, PhD, Sutura's Chief Science Officer.
Sutura believes that these successful initial cases of the 12F device will only add to the positive feedback the SuperStitch product line has received to date.
Dr. Galli, speaking from Como, Italy, added, "We are very pleased to have had the opportunity to perform these procedures for the first time here in Italy as we did with Sutura's 6 and 8F SuperStitch devices.
Dr. Nobles further commented that Dr. Galli has been a crucial component in the development of the SuperStitch technology as he has performed many cases using the SuperStitch and is in the process of completing a 100 patient study for Sutura with initial results that are demonstrating positive outcomes for the SuperStitch products.
"I believe the SuperStitch device for closing large bore holes is superior to any competitive technologies I have worked with and I feel that this device can become the Gold Standard for closure of large diameter holes," noted Dr. Galli.
About Sutura, Inc.
Sutura®, Inc. (www.Suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.
Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.
Forward-Looking Information Is Subject to Risk and Uncertainty
Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", "appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the ability of the company to raise additional funds necessary for the continued operation of the company, acceptance of the SuperStitch® and HeartStitch® devices by medical providers and the marketplace in general, the ability of the company to establish a successful strategic relationships or to complete strategic transactions with third parties, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.
Source: Sutura
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
